All In Biotech

Drug Trial Radar · NCT05984277

A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.

A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer (mNSCLC).

Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 895 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

895

Actual

Start

Oct 24, 2023

Primary completion

Aug 17, 2026

Study completion Nov 12, 2027

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Aug 9, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of eVOLVE-Lung02 is to test the effectiveness (efficacy) and measure the safety of volrustomig in combination with chemotherapy compared with pembrolizumab in combination with chemotherapy as 1L treatment in participants with mNSCLC in PD-L1 \< 50%.

Conditions

  • Metastatic Non-small Cell Lung Cancer

Interventions

  • VolrustomigDrug

    Volrustomig

  • PembrolizumabDrug

    Pembrolizumab

  • CarboplatinDrug

    Carboplatin

  • PaclitaxelDrug

    Paclitaxel

  • PemetrexedDrug

    Pemetrexed

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS) (using BICR assessments according to RECIST 1.1)Time frame: Up to approximately 6 years
  2. Overall Survival (OS), in PD-L1-negative participants.Time frame: Up to approximately 6 years

Locations

231 sites in 25 countries. Site status is shown where the registry gives one.

  • Research Site

    Hot Springs, Arkansas

  • Research Site

    Springdale, Arkansas

  • Research Site

    Long Beach, California

  • Research Site

    Lone Tree, Colorado

  • Research Site

    Orlando, Florida

  • Research Site

    St. Petersburg, Florida

  • Research Site

    Indianapolis, Indiana

  • Research Site

    Des Moines, Iowa

  • Research Site

    Baltimore, Maryland

  • Research Site

    Towson, Maryland

  • Research Site

    Detroit, Michigan

  • Research Site

    Grand Island, Nebraska

  • Research Site

    Lincoln, Nebraska

  • Research Site

    Omaha, Nebraska

  • Research Site

    East Syracuse, New York

  • Research Site

    Columbus, Ohio

  • Research Site

    Portland, Oregon

  • Research Site

    Horsham, Pennsylvania

  • Research Site

    Pittsburgh, Pennsylvania

  • Research Site

    Memphis, Tennessee

  • Research Site

    Nashville, Tennessee

  • Research Site

    Nashville, Tennessee

  • Research Site

    Houston, Texas

  • Research Site

    Irving, Texas

  • Research Site

    Fairfax, Virginia

  • Research Site

    Tacoma, Washington

  • Research Site

    CABA, Argentina

  • Research Site

    CABA, Argentina

  • Research Site

    CABA, Argentina

  • Research Site

    Córdoba, Argentina

  • Research Site

    Córdoba, Argentina

  • Research Site

    La Plata, Argentina

  • Research Site

    La Plata, Argentina

  • Research Site

    Rosario, Argentina

  • Research Site

    Clayton, Australia

  • Research Site

    Fitzroy, Australia

  • Research Site

    Heidelberg, Australia

  • Research Site

    South Brisbane, Australia

  • Research Site

    Sydney, Australia

  • Research Site

    Linz, Austria

Showing 40 of 231 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.